Updated just now · Live
Stock analysis, price data, and AI-powered insights for Nuvalent, Inc (NUVL).
Nuvalent, Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for NUVL.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). NUVL Stock Intelligence Report. [stoxpulse.com/stocks/nuvl]
Disclaimer: The information on this page about Nuvalent, Inc (NUVL) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Nuvalent, Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Nuvalent to Present Pivotal Data from ALKOVE-1 Tri...
7h ago
Nuvalent, Inc - Nuvalent anticipates U.S. commerci...
4d ago
StoxPulse AI results for NUVL: Pulse Score 49/100. Primary sentiment trends from 4 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$8.51B
P/E Ratio
—
EPS
$-1.70
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Nuvalent, Inc - Nuvalent anticipates U.S. commercial launch of Zidesamtinib in 2026
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Nuvalent Reports Zidesamtinib Shows Activity In Pre-Treated ROS1+ Lung Cancer With Strong Brain Penetration Data At AACR 2026